Antibodies to vla-1
AssigneeBiogen Idec MA Inc.
InventorsMichael Karpusas, Paul D Lyne, Jose William B Saldanha, Ellen A Garber
Life of this patent
Estimating the term…
Abstract
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
Claims42
An anti-VLA-1 antibody whose light chain complementarity determining regions are defined by amino acid residues 24 to 33, 49 to 55, and 88 to 96 of SEQ ID NO:
- 1, and whose heavy chain complementarity determining regions are defined by amino acid residues 31 to 35, 50 to 65, and 98 to 107 of SEQ ID NO:2.
An isolated nucleic acid comprising a coding sequence for SEQ ID NO:1.
An isolated nucleic acid comprising a coding sequence for SEQ ID NO:2.
An isolated nucleic acid comprising a coding sequence for the light chain of an antibody produced by hybridoma mAQC2 (ATCC accession number PTA3273).
An isolated nucleic acid comprising a coding sequence for the heavy chain of an antibody produced by hybridoma mAQC2 (ATCC accession number PTA3273).
An isolated nucleic acid comprising a coding sequence for the light chain of an antibody produced by cell line hAQC2 (ATCC accession number PTA3275).
An isolated nucleic acid comprising a coding sequence for the heavy chain of an antibody produced by cell line hAQC2 (ATCC accession number PTA3275).
An isolated nucleic acid comprising a coding sequence for the heavy chain of an antibody produced by cell line haAQC2 (ATCC accession number PTA3274).
An isolated nucleic acid comprising a coding sequence for the heavy chain of an antibody produced by cell line hsAQC2 (ATCC accession number PTA3356).
An isolated nucleic acid comprising a coding sequence for residues 1 to 106 of SEQ ID NO:3.
An isolated nucleic acid comprising a coding sequence for residues 1 to 118 of SEQ ID NO:4.
A cell of hybridoma mAQC2 (ATCC accession number PTA3273).
A cell of cell line hAQC2 (ATCC accession number PTA3275).
A cell of cell line haAQC2 (ATCC accession number PTA3274).
A cell of cell line hsAQC2 (ATCC accession number PTA3356).
A computer for producing a three-dimensional representation of:
- (a) a molecular complex, wherein said molecular complex is defined by the set of structure coordinates of a complex of a chimeric I domain of a α1β1 integrin RΔH and a humanized antibody hAQC2, according to FIG. 19;
- or
- (b) a homologue of said molecular complex, said homologue having a root mean square deviation from the backbone atoms of said amino acids of not more than 0.65 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises at least a portion of the structure coordinates of said complex, according to FIG. 19;
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- and
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation.
A computer for producing a three-dimensional representation of a molecule or molecular complex comprising:
- a) a first binding site defined by structure coordinates of hAQC2 amino acids comprising at least seven of light chain residues Asn30, Tyr48, Trp90, Ser91, Asn93 and Tip95, and heavy chain residues Ser30, Arg31, Trp47, Ser52, Gly53, His56, Tyr58, Phe99, Gly100 and Asp101 according to FIG. 19;
- or
- b) a homologue of said molecule or molecular complex, wherein said homologue comprises a second binding site that has a root mean square deviation from the backbone atoms of the hAQC2 amino acids of not more than 1.10 Å;
- and wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of hAQC2 amino acids comprising at least seven light chain residues Asn30, Tyr48, Trp90, Ser91, Asn93 and Trp95, and heavy chain residues Ser30, Arg31, Trp47, Ser52, Gly53, His56, Tyr58, Phe99, Gly100 and Asp101 according to FIG. 19;
- and
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation.
A computer for producing a three-dimensional representation of:
- (a) a first binding site defined by structure coordinates of hAQC2 amino acids comprising at least seven of light chain residues Asn30, Tyr48, Trp90, Ser91, Asn93 and Trp95, and heavy chain residues Ser30, Arg31, Trp47, Ser52, Gly53, His56, Tyr58, Phe99, Gly100 and Asp101, according to FIG. 19;
- or
- (b) a second binding site of a homologue that has a root mean square deviation from the backbone atoms of the hAQC2 amino acids of not more than 1.10 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of hAQC2 amino acid acids selected from a group comprising at least seven of light chain residues Asn30, Tyr48, Trp90, Ser91, Asn93 and Trp95, and heavy chain residues Ser30, Arg31, Trp47, Ser52, Gly53, His56, Tyr58, Phe99, Gly100 and Asp101, according to FIG. 19;
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation.
A method for identifying an inhibitor of an I domain of an integrin comprising the steps of:
- (a) using structure coordinates of hAQC2 amino acids comprising at least seven of light chain residues Asn30, Tyr48, Trp90, Ser91, Asn93 and Trp95, and heavy chain residues Ser30, Arg31, Trp47, Ser52, Gly53, His56, Tyr58, Phe99, Gly100 and Asp101, according to FIG. 19 or ± a root mean square deviation from the backbone atoms of said hAQC2 amino acids not more than 1.10 Å, to generate a three-dimensional structure of a binding site;
- (b) employing said three-dimensional structure to design or select a potential antagonist;
- (c) synthesizing said potential antagonist;
- and
- (d) contacting said potential antagonist with hAQC2 to determine the ability of said potential antagonist to interact with hAQC2, wherein the ability of said potential antagonist to interact with hAQC2 indicates that the potential antagonist is an inhibitor of the I domain.
A computer for producing a three-dimensional representation of a molecule or molecular complex comprising:
- a) a first binding site defined by structure coordinates of I domain amino acid residues Asp154, Ser156, Asn157, Ser158, Tyr160, Glu192, Gln218, Arg219, Gly220, Gly221, Arg222, Gln223, Thr224, Asp257, His261, Asn263, Arg291, and Leu294, according to FIG. 19;
- or
- b) a homologue of said molecule or molecular complex, wherein said homologue comprises a second binding site that has a root mean square deviation from the backbone atoms of said I domain amino acids not more than 0.92 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of I domain amino acid residues Asp154, Ser156, Asn157, Ser158, Tyr160, Glu192, GIn218, Arg219, Gly220, Gly221, Arg222, Gln223, Thr224, Asp257, His261, Asn263, Arg291, and Leu294, according to FIG. 19;
- and
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- and
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation.
A computer for producing a three-dimensional representation of:
- (a) a first binding site defined by structure coordinates of I domain amino acids residues Asp154, Ser156, Asn157, Ser158, Tyr160, Glu192, Gln218, Arg219, Gly220, Gly221, Arg222, Gln223, Thr224, Asp257, His261, Asn263, Arg291, and Leu294, according to FIG. 19;
- or
- (b) a second binding site of a homologue that has a root mean square deviation from the backbone atoms of said I domain amino acids not more than 0.92 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises structure coordinates of I domain amino residues Asp154, Ser156, Asn157, Ser158, Tyr160, Glu192, Gln218, Arg219, Gly220, Gly221, Arg222, Gln223, Thr224, Asp257, His261, Asn263, Arg291, and Leu294, according to FIG. 19;
- and
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- and
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation;
A computer for producing a three-dimensional representation of a molecule or molecular complex comprising:
- a) a first binding site defined by structure coordinates of I domain amino acids comprising at least three of residues Glu 192, Gln218, Arg219, Gly220, and Gly221, according to FIG. 19;
- or
- b) a homologue of said molecule or molecular complex, wherein said homologue comprises a second binding site that has a root mean square deviation from the backbone atoms of said I domain amino acids not more than 0.30 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of I domain amino acids comprising at least three of residues Glu192, Gln218, Arg219, Gly220, and Gly221, according to FIG. 19;
- and
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- and
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation;
A computer for producing a three-dimensional representation of:
- (a) a first binding site defined by structure coordinates of I domain amino acids comprising at least three of residues Glu192, Gln218, Arg219, Gly220, and Gly221, according to FIG. 19;
- or
- (b) a second binding site of a homologue that has a root mean square deviation from the backbone atoms of said I domain amino acids not more than 0.30 Å;
- wherein said computer comprises:
- (i) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of I domain amino acids comprising at least three of residues Glu192, Gln218, Arg219, Gly220, and Gly221, according to FIG. 19;
- (ii) a working memory for storing instructions for processing said machine-readable data;
- (iii) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine-readable data storage medium for processing said machine readable data into said three-dimensional representations;
- and
- (iv) a display coupled to said central-processing unit for displaying said three-dimensional representation;
A method for identifying an inhibitor of an I domain of an integrin comprising the steps of:
- (a) using the structure coordinates of I domain amino acids residues Asp154, Ser156, Asn157, Ser158, Tyr160, Glu192, Gln218, Arg219, Gly220, Gly221, Arg222, Gln223, Thr224, Asp257, His261, Asn263, Arg291, and Leu294, according to FIG. 19, to generate a three-dimensional structure of a binding site;
- (b) employing said three-dimensional structure to design or select a potential antagonist;
- (c) synthesizing said potential antagonist;
- and
- (d) contacting said potential antagonist with I domain to determine the ability of said potential antagonist to interact with I domain, wherein the ability of said potential antagonist to interact with the I domain indicates that the potential antagonist is an inhibitor of the I domain.
A method for identifying an inhibitor of an I domain of an integrin comprising the steps of:
- (a) using the structure coordinates of at least three of I domain amino acids comprising residues Glu192, Gln218, Arg219, Gly220, and Gly221, according to FIG. 19, or ±a root mean square deviation from the backbone atoms of said I domain amino acids not more than 0.30 Å, to generate a three-dimensional structure of a binding site;
- (b) employing said three-dimensional structure to design or select a potential antagonist;
- (c) synthesizing said potential antagonist;
- and
- (d) contacting said potential antagonist with I domain to determine the ability of said potential antagonist to interact with I domain of integrin, wherein the ability of said potential antagonist to interact with the I domain indicates that the potential antagonist is an inhibitor of the I domain.
Dependencies are inferred from the claim text.